Parkview Specialty Pharmacy receives Patient Choice Award from Managed Markets Insight and Technology

FORT WAYNE, IND. – MAY 12, 2022 – The Parkview Specialty Pharmacy, which supports patients with chronic and complex conditions, has been recognized with the Managed Markets Insight and Technology (MMIT) Specialty Pharmacy Patient Choice Award.

Each year, MMIT recognizes specialty pharmacies that provide best-in-class customer satisfaction and overall patient care within three categories: Payer/ Pharmacy Benefit Manager, Hospital and Health System, and Independent and Retail. Parkview was recognized in the Hospital and Health System category.

The Specialty Pharmacy Patient Choice Award is given to the organization that delivers the best patient experience in each category as measured by the average Net Promoter Score (NPS) in the Zitter Insights Specialty Pharmacy Patient Satisfaction Survey. NPS is a cross-industry standardized index ranging from -100 to 100 that measures the willingness of customers to recommend a company’s products or services to others.

Since first participating in the survey in 2020, the Parkview Specialty Pharmacy has consistently earned market-leading NPS scores. In the most recent survey, patients gave the service a perfect NPS score of 100.

“We started the Parkview Specialty Pharmacy to enhance the specialty medication experience and improve clinical outcomes for our patients,” said Chris Jellison, vice president, Pharmacy, Parkview Health. “We are greatly honored to receive this award, which directly reflects how our services are impacting patients across northeast Indiana and northwest Ohio.”

Parkview Health launched the Parkview Specialty Pharmacy in August 2019 in partnership with Trellis Rx, a technology-enabled specialty pharmacy services provider. Through this service, pharmacists and pharmacy liaisons are integrated into care teams across seven specialty areas including oncology, rheumatology, gastroenterology and infectious disease to provide patients with coordinated, high-touch care needed to improve adherence and outcomes.

To date, the Parkview Specialty Pharmacy has supported more than 4,000 patients and achieved industry-leading clinical outcomes across specialties.

In rheumatology, pharmacists collected 100% of patients’ RAPID3 scores – a recognized measure of disease severity – and completed interventions to help more than 32% of these patients with high or worsening scores improve their health status.

Additionally, across all specialties, Parkview Specialty Pharmacy patients are more than 95% adherent to their therapy regimens, far exceeding national averages.

To learn more about the Parkview Specialty Pharmacy, visit their website.